Given the potential of combining NLRP3-targeted therapies with immune checkpoint inhibitors, clinical trials should be designed to evaluate the safety and efficacy of this combination therapy in patients with advanced urogenital cancers. This evidence concerns the gene NLRP3 and urogenital neoplasm.